诺泰生物
(688076)
| 流通市值：118.75亿 | | | 总市值：118.75亿 |
| 流通股本：3.15亿 | | | 总股本：3.15亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 565,595,756.61 | 1,624,801,884.87 | 1,252,252,784.74 | 831,498,746.79 |
| 营业收入 | 565,595,756.61 | 1,624,801,884.87 | 1,252,252,784.74 | 831,498,746.79 |
| 二、营业总成本 | 375,513,297.49 | 1,132,858,689.8 | 832,401,194.11 | 552,758,685.92 |
| 营业成本 | 168,524,396.52 | 525,056,939.13 | 384,214,016.79 | 271,763,389.66 |
| 税金及附加 | 3,075,764.81 | 9,222,004.54 | 7,171,997.74 | 4,062,312.08 |
| 销售费用 | 25,532,789.91 | 61,966,884.86 | 46,441,615.96 | 28,667,949.96 |
| 管理费用 | 91,662,567.56 | 290,726,348.99 | 205,971,512.31 | 130,667,954.41 |
| 研发费用 | 78,472,550.38 | 227,445,085.48 | 172,750,863.81 | 112,494,851.21 |
| 财务费用 | 8,245,228.31 | 18,441,426.8 | 15,851,187.5 | 5,102,228.6 |
| 其中:利息费用 | 12,894,124.47 | 34,749,230.75 | 23,090,156.75 | 13,884,208.1 |
| 其中:利息收入 | 1,912,012.2 | 7,981,132.22 | 5,553,161.61 | 3,148,670.73 |
| 加:公允价值变动收益 | - | -2,791,811.68 | -4,696,871.91 | -3,133,714.68 |
| 加:投资收益 | 647,472.46 | 1,068,492.31 | 97,288.38 | -463,054.67 |
| 资产处置收益 | - | 496,916.25 | -32,858.25 | - |
| 资产减值损失(新) | -18,902,820.29 | -36,426,468.1 | -16,863,144.47 | -10,140,579.59 |
| 信用减值损失(新) | 2,945,437.29 | -20,850,264.07 | -18,509,225.46 | -13,073,760.27 |
| 其他收益 | 2,729,571.37 | 14,778,384.23 | 9,582,615.46 | 6,981,052.34 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 177,502,119.95 | 448,218,444.01 | 389,429,394.38 | 258,910,004 |
| 加:营业外收入 | 117,440.51 | 1,225,845.64 | 981,200.39 | 385,275.21 |
| 减:营业外支出 | 274,591.98 | 10,940,137.08 | 5,171,273.64 | 2,332,626.47 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 177,344,968.48 | 438,504,152.57 | 385,239,321.13 | 256,962,652.74 |
| 减:所得税费用 | 29,470,919.22 | 38,685,704.19 | 34,542,851.04 | 25,197,489.05 |
| 六、净利润 | 147,874,049.26 | 399,818,448.38 | 350,696,470.09 | 231,765,163.69 |
| 持续经营净利润 | 147,874,049.26 | 399,818,448.38 | 350,696,470.09 | 231,765,163.69 |
| 归属于母公司股东的净利润 | 152,616,552.22 | 404,389,990.7 | 350,247,058.35 | 227,161,523.34 |
| 少数股东损益 | -4,742,502.96 | -4,571,542.32 | 449,411.74 | 4,603,640.35 |
| (一)基本每股收益 | 0.69 | 1.88 | 1.62 | 1.06 |
| (二)稀释每股收益 | 0.68 | 1.84 | 1.58 | 1.01 |
| 九、综合收益总额 | 147,874,049.26 | 399,818,448.38 | 350,696,470.09 | 231,765,163.69 |
| 归属于母公司股东的综合收益总额 | 152,616,552.22 | 404,389,990.7 | 350,247,058.35 | 227,161,523.34 |
| 归属于少数股东的综合收益总额 | -4,742,502.96 | -4,571,542.32 | 449,411.74 | 4,603,640.35 |
| 公告日期 | 2025-04-23 | 2025-04-23 | 2024-10-23 | 2024-08-23 |
| 审计意见(境内) | | 带强调事项段的无保留意见 | | |